Veru Inc
FMW
Company Profile
Business description
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
Contact
2916 North Miami Avenue
Suite 1000
MiamiFL33127
USAT: +1 305 509-6897
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 September 2025
Employees
210
Stocks News & Analysis
stocks
ASX shares plunge but remain undervalued
Shares drop 17% after guidance is revised but we still see value.
stocks
Ask the analyst: Why have markets shunned APA Group?
Australia's premier gas infrastructure firm used to be a market darling, but its shares have taken a severe de-rating in recent years.
stocks
The 10 best US dividend stocks
These undervalued stocks with reliable dividends are worth considering.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,431.90 | 111.80 | -1.31% |
| CAC 40 | 7,408.64 | 22.40 | -0.30% |
| DAX 40 | 20,132.85 | 81.94 | -0.41% |
| Dow JONES (US) | 42,235.49 | 297.04 | 0.71% |
| FTSE 100 | 8,224.19 | 24.30 | -0.29% |
| HKSE | 18,874.14 | 190.15 | -1.00% |
| NASDAQ | 19,016.10 | 145.53 | -0.76% |
| Nikkei 225 | 39,190.40 | 414.69 | -1.05% |
| NZX 50 Index | 12,827.33 | 68.65 | -0.53% |
| S&P 500 | 5,821.75 | 5.29 | -0.09% |
| S&P/ASX 200 | 8,191.90 | 102.20 | -1.23% |
| SSE Composite Index | 3,160.75 | 7.77 | -0.25% |